Skip to main content

Table 3 Top 10 adverse effects (all grade) associated with gefitinib versus erlotinib

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Adverse effects Gefitinib group (event/total) Erlotinib group (event/total) RR (95% CI) P value Heterogeneity
I2 (%) P value
Skin rash 673/1099 650/944 0.83 (0.74–0.94) 0.003 68 0.0009
Diarrhea 298/999 273/745 0.83 (0.73–0.95) 0.005 47 0.06
Nausea/Vomiting 107/639 139/531 0.71 (0.32–1.57) 0.4 74 0.002
Fatigue 124/639 149/531 0.47 (0.23–0.95) 0.04 81 < 0.0001
Anorexia 53/403 40/310 0.98 (0.40–2.42) 0.97 78 0.001
Interstitial lung disease 35/949 19/723 1.38 (0.78–2.44) 0.26 0 0.65
Stomatitis 12/260 29/169 0.29 (0.15–0.54) 0.0001 24 0.27
Elevated liver enzymes 366/931 264/680 1.16 (0.85–0.1.56) 0.35 61 0.04
Infection 45/686 23/466 1.53 (0.93–2.51) 0.1 23 0.27
Neutropenia 61/399 51/379 1.19 (0.85–1.66) 0.32 0 0.55